A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer.

ABSTRACT:

Purpose

Bladder cancer (BLCA) is one of the most common cancers worldwide. In a large proportion of BLCA patients, disease recurs and/or progress after resection, which remains a major clinical issue in BLCA management. Therefore, it is vital to identify prognostic biomarkers for treatment stratification. We investigated the efficiency of CpG methylation for the potential to be a prognostic biomarker for patients with BLCA.

Patients and methods

Overall, 357 BLCA patients from The Cancer Genome Atlas (TCGA) were randomly separated into the training and internal validation cohorts. Least absolute shrinkage and selector operation (LASSO) and support vector machine-recursive feature elimination (SVM-RFE) were used to select candidate CpGs and build the methylation risk score mod

SUBMITTER: Guo Y 

PROVIDER: S-EPMC8440888 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature